PROGNOSTIC VALUE OF A T HELPER 1 URINARY CYTOKINE RESPONSE AFTER INTRAVESICAL BACILLUS CALMETTE-GUERIN TREATMENT FOR SUPERFICIAL BLADDER CANCER
- 1 January 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 167 (1) , 364-367
- https://doi.org/10.1016/s0022-5347(05)65469-9
Abstract
Purpose: Interleukin (IL)-2 and interferon-γ are released during T helper 1 lymphocyte responses, while IL-10 is released during T helper 2 responses. We evaluated the prognostic value of urinary IL-2, interferon-γ and IL-10 levels in patients with superficial bladder cancer treated with bacillus Calmette-Guerin (BCG) instillation Methods: Urinary IL-2, interferon-γ and IL-10 were measured by enzyme-linked immunosorbent assay in 37 patients receiving BCG for stages Ta/T1 superficial bladder cancer, and carcinoma in situ. Measurements were made after instillations 5 and 6 during a course of 6 weekly instillations of 150 mg. BCG, Pasteur strain. Correlations of cytokine levels with the clinical outcome were evaluated using the log rank test Results: Median followup was 29 months. Patients with urinary IL-2 less than 27 pg./μmol. creatinine were significantly more likely to have recurrences than those with higher values (log rank test p = 0.0009). Urinary IL-10 and interferon-γ levels had no apparent impact on the risk of recurrence or progression Conclusion: Urinary IL-2 levels may serve to identify patients at risk for bladder cancer recurrence after a single course of BCG and, thus, to tailor individual treatment.Keywords
This publication has 19 references indexed in Scilit:
- MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDYJournal of Urology, 2000
- URINARY INTERLEUKIN-8/CREATININE LEVEL AS A PREDICTOR OF RESPONSE TO INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY IN BLADDER TUMOR PATIENTSJournal of Urology, 1997
- Urinary Cytokines During Intravesical Bacillus Calmetteguerin Therapy for Superficial Bladder CancerJournal of Urology, 1996
- Analysis of early failures after intravesical instillation therapy with bacille Calmette‐Guerin for carcinoma in situ of the bladderBritish Journal of Urology, 1995
- Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapyCancer Immunology, Immunotherapy, 1994
- Dissecting the Immunobiological Effects of Bacillus Calmette-Guérin (BCG) In Vitro: Evidence of a Distinct BCG-Activated Killer (BAK) Cell PhenomenonJournal of Urology, 1993
- Urinary interleukins in patients receiving intravesical bacillus calmette-guerin therapy for superficial bladder cancerCancer, 1989
- Superficial Bladder Cancer Treated with Bacillus Calmette-Guerin: A Multivariate Analysis of Factors Affecting Tumor ProgressionJournal of Urology, 1989
- Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer.Journal of Clinical Oncology, 1988
- Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder TumorsJournal of Urology, 1976